Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
PMCID: PMC8566728.
Oncolytic BHV-1 is sufficient to induce immunogenic cell death and synergizes with low-dose chemotherapy to dampen immunosuppressive T regulatory cells
If a patient has: Chronic extravascular hemolysis Increased 2,3-BPG Normal G6PD think pyruvate kinase deficiency
These are dose-dependent effects that careful escalation manages rather than eliminates and knowing that going in changes how patients experience the early weeks of treatment
10.1097/00008571-200106000-00003 Pharmacogenetics 87 HoR
US$ 21.28
US$ 24.64
US$ 25.68
US$ 29.20
US$ 28.47
US$ 20.64
US$ 22.36
US$ 23.38
US$ 23.30
US$ 29.85
US$ 27.57
